I-Mab Future Growth
Future criteria checks 0/6
I-Mab is forecast to grow earnings and revenue by 1.9% and 47.1% per annum respectively while EPS is expected to grow by 19.7% per annum.
Key information
1.9%
Earnings growth rate
19.7%
EPS growth rate
Biotechs earnings growth | 35.1% |
Revenue growth rate | 47.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 13 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -106 | -59 | N/A | 3 |
12/31/2025 | N/A | -75 | -53 | N/A | 3 |
12/31/2024 | N/A | -35 | -40 | N/A | 3 |
6/30/2024 | 3 | -206 | N/A | N/A | N/A |
3/31/2024 | 4 | -205 | N/A | N/A | N/A |
12/31/2023 | 4 | -206 | -185 | -184 | N/A |
9/30/2023 | -15 | -253 | N/A | N/A | N/A |
6/30/2023 | -35 | -295 | N/A | N/A | N/A |
3/31/2023 | -35 | -331 | N/A | N/A | N/A |
12/31/2022 | -32 | -364 | -167 | -160 | N/A |
9/30/2022 | -7 | -338 | N/A | N/A | N/A |
6/30/2022 | 18 | -344 | -171 | -164 | N/A |
3/31/2022 | 17 | -365 | -169 | -164 | N/A |
12/31/2021 | 14 | -367 | -158 | -153 | N/A |
9/30/2021 | 247 | -103 | 45 | 48 | N/A |
6/30/2021 | 242 | -4 | 51 | 53 | N/A |
3/31/2021 | 237 | 34 | 58 | 59 | N/A |
12/31/2020 | 236 | 72 | 65 | 66 | N/A |
9/30/2020 | N/A | -140 | -119 | -118 | N/A |
6/30/2020 | 2 | -171 | -119 | -117 | N/A |
3/31/2020 | 3 | -190 | -121 | -120 | N/A |
12/31/2019 | 4 | -213 | -126 | -125 | N/A |
9/30/2019 | 6 | -172 | -111 | -109 | N/A |
6/30/2019 | 7 | -159 | -90 | -88 | N/A |
3/31/2019 | 8 | -111 | -68 | -66 | N/A |
12/31/2018 | 8 | -59 | -43 | -41 | N/A |
12/31/2017 | 2 | -46 | N/A | -39 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0VY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0VY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0VY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0VY is forecast to have no revenue next year.
High Growth Revenue: 0VY is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0VY's Return on Equity is forecast to be high in 3 years time